Indivior (LSE:INDV) Insider Ownership : 1.59 % (As of May. 22, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Indivior Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Indivior's insider ownership is 1.59%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Indivior's Institutional Ownership is 28.87%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Indivior's Float Percentage Of Total Shares Outstanding is 0.00%.

Indivior Insider Ownership Historical Data

The historical data trend for Indivior's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Indivior Insider Ownership Chart

Indivior Historical Data

The historical data trend for Indivior can be seen below:

	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30
Insider Ownership	1.56	1.56	1.56	1.56	1.57	1.58	1.59	1.59	1.59	1.59

Indivior Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Indivior (LSE:INDV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Indivior PLC (LSE:INDV) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

INDV:USA INDVl:UK 2IVB:Germany

Address

234 Bath Road, Slough, Berkshire, GBR, SL1 4EE

Website

http://www.indivior.com

Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs based on buprenorphine for treatment of opioid dependence. The vast majority of Indivior's revenue is generated in the United States, followed by the rest of the world. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.